Search research articles
Contact Us
Filters
Showing results (111-120 of 121) with videos related to
Page
of 13
Sort By:
Pediatric Nephrology (Berlin, Germany)
|
March 21, 1998
Lack of large, homozygous deletions of the nephronophthisis 1 region in Joubert syndrome type B. APN Study Group. Arbeitsgemeinschaft für Pädiatrische Nephrologie
F Hildebrandt, H G Nothwang, U Vossmerbäumer, et al.
Pediatrics
|
January 26, 1999
Clinical and genetic risk factors for cystic fibrosis-related liver disease
M Wilschanski, J Rivlin, S Cohen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 8, 2014
Whole-genome sequencing reveals complex mechanisms of intrinsic resistance to BRAF inhibition
S Turajlic, S J Furney, G Stamp, et al.
Cancer Causes & Control : CCC
|
July 13, 2013
An institutional strategy to increase minority recruitment to therapeutic trials
Victoria V Anwuri, Lannis E Hall, Katherine Mathews, et al.
Pediatrics
|
January 30, 2013
Management of type 2 diabetes mellitus in children and adolescents
Shelley C Springer, Janet Silverstein, Kenneth Copeland, et al.
Pediatrics
|
January 30, 2013
Management of newly diagnosed type 2 Diabetes Mellitus (T2DM) in children and adolescents
Kenneth C Copeland, Janet Silverstein, Kelly R Moore, et al.
Molecular Medicine (Cambridge, Mass.)
|
October 31, 2000
Chalcone, acyl hydrazide, and related amides kill cultured Trypanosoma brucei brucei
L Troeberg, X Chen, T M Flaherty, et al.
Journal of Oncology Practice
|
October 17, 2013
Coaching intervention as a strategy for minority recruitment to cancer clinical trials
Paula M Fracasso, Sherry A Goodner, Allison N Creekmore, et al.
Cardiovascular Diabetology
|
January 28, 2023
Deletion of Tbc1d4/As160 abrogates cardiac glucose uptake and increases myocardial damage after ischemia/reperfusion
C Binsch, D M Barbosa, G Hansen-Dille, et al.
British Journal of Cancer
|
September 19, 2002
A phase I trial of antibody directed enzyme prodrug therapy (ADEPT) in patients with advanced colorectal carcinoma or other CEA producing tumours
R J Francis, S K Sharma, C Springer, et al.
Page
of 13
Search research articles
Search
Showing results (111-120 of 121) with videos related to
Sort By:
Page
of 13
Pediatric Nephrology (Berlin, Germany)
|
March 21, 1998
Lack of large, homozygous deletions of the nephronophthisis 1 region in Joubert syndrome type B. APN Study Group. Arbeitsgemeinschaft für Pädiatrische Nephrologie
F Hildebrandt, H G Nothwang, U Vossmerbäumer, et al.
Pediatrics
|
January 26, 1999
Clinical and genetic risk factors for cystic fibrosis-related liver disease
M Wilschanski, J Rivlin, S Cohen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 8, 2014
Whole-genome sequencing reveals complex mechanisms of intrinsic resistance to BRAF inhibition
S Turajlic, S J Furney, G Stamp, et al.
Cancer Causes & Control : CCC
|
July 13, 2013
An institutional strategy to increase minority recruitment to therapeutic trials
Victoria V Anwuri, Lannis E Hall, Katherine Mathews, et al.
Pediatrics
|
January 30, 2013
Management of type 2 diabetes mellitus in children and adolescents
Shelley C Springer, Janet Silverstein, Kenneth Copeland, et al.
Pediatrics
|
January 30, 2013
Management of newly diagnosed type 2 Diabetes Mellitus (T2DM) in children and adolescents
Kenneth C Copeland, Janet Silverstein, Kelly R Moore, et al.
Molecular Medicine (Cambridge, Mass.)
|
October 31, 2000
Chalcone, acyl hydrazide, and related amides kill cultured Trypanosoma brucei brucei
L Troeberg, X Chen, T M Flaherty, et al.
Journal of Oncology Practice
|
October 17, 2013
Coaching intervention as a strategy for minority recruitment to cancer clinical trials
Paula M Fracasso, Sherry A Goodner, Allison N Creekmore, et al.
Cardiovascular Diabetology
|
January 28, 2023
Deletion of Tbc1d4/As160 abrogates cardiac glucose uptake and increases myocardial damage after ischemia/reperfusion
C Binsch, D M Barbosa, G Hansen-Dille, et al.
British Journal of Cancer
|
September 19, 2002
A phase I trial of antibody directed enzyme prodrug therapy (ADEPT) in patients with advanced colorectal carcinoma or other CEA producing tumours
R J Francis, S K Sharma, C Springer, et al.
Page
of 13